Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

C-kit expression and mutational analysis in medulloblastoma.

Susan Chilton-Macneill1, Michael Ho, Cynthia Hawkins

  • 1Department of Pediatric Laboratory Medicine, Hospital for Sick Children, 555 University Avenue, M5G 1X8, Toronto, ON, Canada.

Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
|November 18, 2004
PubMed
Summary

Proto-oncogene c-kit is expressed in medulloblastoma, a common childhood brain tumor. Its activation in these tumors occurs independently of mutations, suggesting alternative therapeutic targets beyond direct c-kit inhibition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-Targeted pan-RAS Inhibition as a Novel Biologic Therapy for Diffuse Midline Glioma.

Neuro-oncology·2026
Same author

Tumor-derived cell-free DNA detected in cerebrospinal fluid enables minimally invasive profiling of pediatric brain tumors.

The Journal of clinical investigation·2026
Same author

Ultrasound-Enhanced Drug Delivery in Pediatric Neuro-Oncology: A New Therapeutic Strategy.

Pharmaceutics·2026
Same author

Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.

Neuro-oncology·2026
Same author

TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

Neuro-oncology·2026
Same author

Multiclass Radiomics-Based Prediction of BRAF Mutation Status in Pediatric Low-Grade Gliomas Using Multisequence MRI.

AJNR. American journal of neuroradiology·2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The proto-oncogene c-kit encodes a receptor tyrosine kinase crucial for cell signaling in proliferation, differentiation, and metastasis.
  • Aberrant c-kit expression or mutations are implicated in various cancers, with imatinib mesylate showing efficacy in certain tyrosine kinase-driven tumors.
  • Medulloblastoma, a malignant pediatric central nervous system tumor, requires better characterization for targeted therapies.

Purpose of the Study:

  • To investigate c-kit expression and mutational status in medulloblastoma.
  • To determine if the stem cell factor/c-kit pathway is involved in medulloblastoma pathogenesis.
  • To explore potential responsiveness of medulloblastoma to imatinib mesylate.

Main Methods:

  • Analysis of c-kit expression in 10 medulloblastoma samples using reverse transcriptase-polymerase chain reaction and immunohistochemistry.

Related Experiment Videos

  • Screening for mutations in exons 9, 11, and 13 of the c-kit gene via direct sequencing.

    • Main Results:

    • All 10 medulloblastoma samples expressed c-kit mRNA.
    • Immunohistochemical analysis confirmed c-kit expression in 9 out of 10 tumors.
    • No mutations were detected in the screened exons (9, 11, and 13) of the c-kit gene.

    Conclusions:

    • Medulloblastoma tumors express c-kit.
    • c-kit activation in medulloblastoma is independent of mutations in the analyzed exons.
    • This suggests that therapeutic strategies targeting c-kit in medulloblastoma may need to consider mechanisms other than direct mutation-induced activation.